Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Wide K et al. | Time course of the increase in 4beta-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy. | 2008 | Br J Clin Pharmacol | pmid:18279471 |
Hukkanen J et al. | The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. | 2015 | Br J Clin Pharmacol | pmid:26095142 |
Gjestad C et al. | 4β-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation? | 2016 | Br J Clin Pharmacol | pmid:26574235 |
de Graan AJ et al. | 4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes. | 2015 | Br J Clin Pharmacol | pmid:26119961 |
Kasichayanula S et al. | Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects. | 2014 | Br J Clin Pharmacol | pmid:24837659 |
Gjestad C et al. | 4β-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients. | 2017 | Br J Clin Pharmacol | pmid:28585378 |
Størset E et al. | The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation. | 2017 | Br J Clin Pharmacol | pmid:28146606 |
Mårde Arrhén Y et al. | A comparison of 4β-hydroxycholesterol : cholesterol and 6β-hydroxycortisol : cortisol as markers of CYP3A4 induction. | 2013 | Br J Clin Pharmacol | pmid:23116409 |
Vanhove T et al. | Pretransplant 4β-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation. | 2017 | Br J Clin Pharmacol | pmid:28603840 |
Diczfalusy U et al. | 4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. | 2011 | Br J Clin Pharmacol | pmid:21219398 |